Study reveals why certain ovarian cancers develop resistance to platinum-based ch... ( SEATTLE A team of researchers led b...)

Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy

Date:2/10/2008

SEATTLE A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. They describe their research online Feb. 10 in the journal Nature.

While these findings are based on the study of ovarian-cancer cells from women with inherited mutations in the BRCA2 gene, they also may help explain the mechanics of cisplatin resistance in ovarian-cancer patients with BRCA1-gene mutations. Together such genetic mistakes are thought to cause about 10 percent of ovarian cancers, according to senior author Toshiyasu (Toshi) Taniguchi, M.D., Ph.D.

Because BRCA1 and BRCA2 have similar functions in terms of DNA repair, we may be able to generalize these findings for women with either mutation, said Taniguchi, an assistant member of the Hutchinson Centers Human Biology and Public Health Sciences divisions.

BRCA2 works to repair damaged DNA; inherited mutations in this gene disrupt that ability, which increases the risk of ovarian and breast cancer. At the same time, such mutations also make cancer cells more vulnerable to DNA-damaging agents such as cisplatin and carboplatin. While ovarian tumors initially respond very well to platinum-based chemotherapy, eventually between 70 percent and 80 percent of advanced-stage ovarian-cancer patients develop a resistance to these drugs.

The majority of advanced-stage ovarian-cancer patients die due to acquired resistance to platinum-based drugs. It is a serious problem, he said.

Taniguchi and colleagues at the Hutchinson Center, University of Washington, Cedars-Sinai Medical Center and the Mayo Clinic have uncovered how such resistance occurs. They found that when exposed to cisplatin, some ovarian-cancer cells develop secondary mutations on their BRCA2 gene that restore the genes ability to repair DNA. This restoration o
'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks

Post Your Comments:

(Date:5/22/2013)... 22, 2013 Following the success of ... franchise Fit Body Boot Camp Kincardine has announced ... Meltdown Challenge starting on June 3rd at its ... Durham Street, Kincardine, Ontario. , Fit Body Boot Camp’s ... motivate local community residents to lose a total of ...

(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 ... and management solutions for social enterprise collaboration platforms, ... a consulting firm based in Chicago, Ill. The ... their products and provide best-in-class solutions for SharePoint ... improve collaboration. , AvePoint’s DocAve Software Platform ...

(Date:5/22/2013)... May 22, 2013 Poor adherence to ... not only medical complications and death (some 125,000 deaths ... non-adherence), but increased health-care costs. It’s been estimated that ... are related to poor medication adherence — a reality ... annually. , Indeed, so dire is the degree of ...

(Date:5/22/2013)... 2013 Athletic-Minded Traveler LLC, a ... released today its 2013 U.S. Business Hotel “Fit ... the company’s recommendation after ongoing research of over ... by the editorial staff. Selection criteria included ... court, etc.), in-room workout choices, healthy food offerings, ...

(Date:5/21/2013)... 22, 2013 Swimsuit season is almost here. ... ® products has begun with a 35% discount. , Cellulite ... Many women get the dreaded cellulite even if they are ... skin where they have been stored as toxic lymph and ... easy fixes, a specific program that works to dissolve the ...

Breaking Medicine News(10 mins):Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2 Health News:2013: The 10 Healthiest Business Hotels in the U.S. 2 Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2

[0] Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance [0] 2013: The 10 Healthiest Business Hotels in the U.S.[0] Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"

... to Health Care Management WASHINGTON, May 5 ... and education organization, announced today that Christine G. Leyden, ... Chief Accreditation Officer for URAC has been recognized as ... in Point magazine. Ms. Leyden will be featured ...

... Education Campaign to Share Her Weight-Loss Journey and Inspire Other ... year, actress Caitlin Van Zandt of "Guiding Light" and "The ... the United States,(1) causing her to also be one of ... at risk of heart disease.(2) Caitlin was at risk of ...

... behind on shots when parents don,t make it to ... Scheduling issues, communication problems and a lack of belief ... some of the biggest hurdles to getting parents to ... report. , Missed appointments were linked to children being ...

... Osteosarcoma is the most common and potentially most dangerous ... of 10 - 25. In "Cancer from A to Z" ... dictionary by Dr. Edward Laughlin, learn that before the 1980,s ... be an intimidating place to enter, and the terminology barrier ...

... Demonstrated in Favorable Response Rates and Hearing PreservationSUNNYVALE, ... ARAY ), a global leader in the ... data using the CyberKnife(R) Robotic Radiosurgery System was ... Association of Neurological Surgeons (AANS) Annual Meeting, May ...

... Help Her get a Good Night,s Sleep at the Samaritan ... This week, sons and daughters all over the community will ... woman in their life - Mom. Flowers, cards and ... are lacking is a good night,s sleep."The need for sleep ...

Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation Video: New Survey Finds 97 Percent of Women Understand Weight Increases Heart Disease Risk - The Leading Cause of Female Death in the United States - Yet 55 Percent Remain Overweight Keeping Appointments Key to Keeping Vaccines on Track 'Cancer from A to Z': A Dictionary of Cancer-Related Terms Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications What does Mom really want for Mothers Day?

(Date:5/22/2013)... FRANCISCO, Calif. , May 22, 2013 ... announced the clinical advancement of three programs in development. ... of a JAK/SYK inhibitor, R348, being developed by Rigel ... two programs are aimed at oncology targets and are ... inhibitor under development by BerGenBio AS (BerGenBio) and a ...

(Date:5/22/2013)... May 22, 2013 WomanCare Global recently ... with an extensive training initiative attended by 90 ... http://photos.prnewswire.com/prnh/20130522/DC18844 ) (Logo: http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) ... a highly effective subdermal implant composed of two ... levonorgestrel (a synthetic form of the hormone progestin). ...

(Date:5/21/2013)... 2013 NxStage Medical, Inc. (Nasdaq: NXTM ... announced that it has entered into new agreements covering ... to DaVita, the kidney care division of DaVita Healthcare Partners ... For the use of products for home hemodialysis ... has executed a second amended and restated National Service ...

Breaking Medicine Technology:Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2 Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3 Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4 WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile 2 NxStage Announces New Agreements with DaVita 2

[0] Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye [0] WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile [0] NxStage Announces New Agreements with DaVita

... /PRNewswire-USNewswire/ -- The Barbara,Ann Karmanos Cancer Institute's Philip ... oncology, presented the outcome,of one of the largest ... America and chaired an education session about the,future ... of,Clinical Oncology (ASCO) annual meeting in Chicago, IL. ...

... 2007 - First-in-human results for,IMC-A12, a monoclonal antibody ... to IGF-1R (insulin-like,growth factor type 1 receptor), were ... of Clinical Oncology in Chicago.,The IGF-IR is expressed ... transmits signals that lead to tumor cell growth ...

Cached Medicine Technology:Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 2 Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 3 Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2 Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3

Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO

The Storz Protege is an anterior segment unit only....

The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....

Compact ultrasonic phacoemulsification system....

... Precisionist workstation is a unique combination ... allowing infinite flexibility for modular hardware ... the demands of changing cataract surgical ... concept in ophthalmic surgical platforms providing ...

Medicine Products:

Storz Phaco Protige Storz Phaco Premiere Compact Ultrasonic Phacoemulsification System Precisionist Phacoemulsification System